When breast cancer is HER2-negative, it means that cancer cells do not contain high levels of the HER2 protein. For this form of breast cancer, there are several treatment choices available, but the prognosis can differ. Represents the human epidermal growth factor receptor 2. The term “Her2” can refer to the her2 gene or her2 protein that the gene is.
Her2 proteins are receptors that are sitting on the surface of the Mammary cells. Typically, they help monitor the development and restoration of healthy tissue in the breast.
However, when the gene HER2 becomes defective and begins to do too many self-copies, it follows an overproduction of protein HER2 on the surface of the breast cells. This can lead to a positive HER2 cancer.
This article gives a general description of a breast cancer group known as Cancers of HER2 negative, which occur for reasons other than an erroneous gene HER2.
We list the current treatment choices for various forms of HER2-negative cancer. As well as prognosis information and survival rates.
To make a diagnosis, a doctor will have to determine the type of breast cancer that a person has. This involves eliminating a small piece of breast tissue during surgery or a biopsy and send it to a laboratory for testing.
The tests reveal what types of genes and proteins are involved in the development of cancer. This helps to assess the care choices that are most suitable.
Most studies divide breast cancer Her2-negative into two types based on the presence or absence of hormonal receptors on the surface of cancer cells.
These types are called breast cancer of the hormonal receiver (HR-positive) And triple-negative cancer of the breast.
Estrogen and progesterone are hormones that contribute to the development of a balanced role in the creation of rising breast tissue. Each hormone has individual protein receptors of its own, which rely on the surface of the breast cells. Receivers take hormones that require cells to grow.
When cancer is positive from HR, the cells use estrogen, progesterone, or both to grow and replicate. When cancer is triple-negative, it means that these hormonal receivers are absent.
These types of cancer have various subtypes because we describe below:
Luminal breast cancers
Cancers of the luminal chest grow in the inner cells or luminaries. These cells border the mammary canals.
Luminal cancers are related to Hr-positives, which means they involve at least one type of hormonal receiver.
Two forms of luminal breast cancer exist. : Luminal A (la) and Luminal B (LB).
The main difference is that between the two groups in the LAM cells, there is less than one protein called Ki-67. The growth rate of tumor cells is regulated by this protein. Tumors appear to evolve more slowly than LB cancers, and they have a greater outcome.
Luminal A breast cancer
According to some studies, about 30 to 70% of breast cancers are chest cancer.
Cancer tends to have the following characteristics:
- Her2-negative cells
- Cells that test positive for estrogen receptors
- Lower levels of Ki-67
- Low-quality tumors
Luminal B breast cancer
Some reports estimate that 10 to 20% of breast cancer are LB breast cancer.
There could be very-negative or her2-positive LB tumors. It appears to have the following features as well:
- Cells that screen positive for receptors of estrogen
Lower Ki-67 amounts
- Superior quality tumors
- Larger tumors
- Greater chance of spreading a lymph node
Triple-negative breast cancer
Roughly 20% of breast cancers are triple-negative—negative studies for three beneficiaries of triple breast cancer: HE2, estrogen, and progesterone.
Most commonly, triple-negative breast cancer occurs in:
- Women who have a BRCA1 gene mutation
- Black girl
- Women under 40 years old
- Premenopausal females